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SECOMET V is a product of the SA based, bio-phannaceutical company called Secomet 
Ltd. This fledgling company was founded in 2002, and specializes in the extraction of 
secondary metabolites from plant cells cultivated in biorectors. Their protocols for the 
propagation of plant cells in large scale were developed in house and have not been 
disclosed. 
The name SECOMET V is a reference name for a plant extract cultivated from plant stem 
cells in a bioreactor. The plant has been used as an oral infusion in folklore medicine in 
South Africa for many generations, and its name has been kept confidential. Furthennore, 
the company also has a confidentiality agreement with the university itself, so that any 
data related to this product may only be disclosed after previous approval by Secomet 
Ltd. 
Empirical evidence suggests that this plant might have a broad spectrum of activity_ It 
also appears that the extract may be effective in delaying the onset of AIDS and 
associated diseases in humans infected with HIV, as well as reducing the amount of 
circulating virus in the blood. 
Currently the company is focusing on this product for the treatment ofHIVIAIDS. One of 
the duties that VCT agreed to undertake was to set up an assay system to test for batch­
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The anti-poxvirus agent SEC~MET V was the reference name for a plant extract 
produced in a bioreactor from primary plant stem cells, whose antiviral activity has been 
widely reported in folklore medicine. It exerted its anti-vaccinia virus activity by 
neutralizing cell-free virus rather than interfering with the downstream events following 
adsorption. The extract was tested against a virus titer of 10f! pfu/ml, exhibiting strong 
vaccinia virus (VV) inhibition (ECso 1150 ± 150 IJglml, when incubated for 60 s prior to 
infection) and mild cytotoxicity in BSC-l host cells (CCso 560 ± 70 IJglml) when 
compared to other plant extracts with anti-VV activity. Furthermore, the inactivation of 
VV was not only dose dependent, but time dependent as welL When incubated with VV 
at an equal titer, at a concentration equal to that of the ECso, there was complete 
inhibition of plaque-forming units (PFU) after 6 min of exposure. However, the extract 
had no impact whatsoever on cell-associated, infectious virus. Moreover, the presence of 
high concentrations of bovine serum albumin (BSA) completely neutralized the anti-VV 
properties of the extract. It was also observed that the extract remained active after being 
subjected to high temperatures and pressure (121 <lC, 15 psi for 30 min) and when size­
fractionated through a 3 Kda cut-off filter, the active fraction was below 3 Kda in size. 
These properties suggested that the active agents were not proteins in nature. HPLC and 
TLC fractionation yielded two distinct active fractions, soluble in both organic and 
aqueous medium. The antivirals interacted strongly with both polar and hydrophobic 
matrices, indicating the presence of hydrophilic and hydrophobic moieties. The HPLC 
conditions developed could be used to further fractionate and purify the antivirals agents 
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Chapter One 

1.0 - Literature Review 
1.1 - Introduction 
The poxvirus family of viruses encompassed a large number of members that infected 
both vertebrate (chordopoxviruses) and invertebrate (entomopoxviruses) organisms 
(reviewed in Moss, 2003). 
The chordopoxvirus sub-family consisted of eight genera, of which vaccinia virus (VV) 
was the representative member of the orthopoxvirus genera. The highly pathogenic and 
now eradicated smallpox virus also belonged to this genus, along with camelpox, 
cowpox, monkeypox, and four other non-medically significant members (reviewed in 
Moss, 2003). 
VV is to date, the workhorse of poxviruses in the research arena. It remains established 
that VV inhibitors were effective to a greater or lesser extent against all other members of 
the poxvirus family. Furthermore, VV was much safer to work with, not requiring high 
biological containment facilities. 
Clinically, the most important of all poxviruses was smallpox (reviewed in Fenner et al., 
1988). Variola virus is the etiological agent of smallpox. A highly transmissible disease 
proved lethal in up to 50 % of cases. It had no natural reservoir and infected humans 
exclusively. 
Due to its severity, a worldwide vaccination campaign was launched, with the ultimate 
goal of eradicating smallpox. The campaign was successful, and in 1981, smallpox was 
officially declared eradicated worldwide by the WHO. However. in reality, vaccination in 
developed countries had been discontinued nearly 15 years prior, and the search for novel 
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A renewed interest in poxvirus prevention and cure was brought about by the terrorist 
attacks on the USA in September 2001 (reviewed in Rotz et al., 2002). Furthermore, 
recent advances in molecular biology had made it possible to produce smallpox in vitro 
most likely by using camelpox as a template (Gubser & Smith, 2002), led officials to 
believe that the world could yet again be vulnerable to smallpox, released deliberately or 
by criminal intent. 
The health hazards posed by poxviruses were further highlighted by the emergence of the 
relatively rare viral zoonosis, human monkeypox (reviewed in Giulio et al., 2004). This 
potentially lethal pathogen was introduced in the USA in the spring of 2003 by imported 
giant Gambian rats sold as exotic pets. Furthermote~ nearly 100 cases have been reported 
in the Democratic Republic of Congo since 1996. 
However, in reality, it was the steady rise in the number of human immune-deficiency 
virus (HIV) infected individuals as well the increase in cancer cases and solid-organ 
recipients, which has made poxviruses clinically significant pathogens once again. What 
all these ailments had in common was that they led to a dangerously weakened immune 
system, increasing the susceptibility to opportunistic pathogens such as Ecthyma 
infectiosum and Molluscum contagiosum, two members ofthe poxvirus family. 
The vaccine used during the smallpox eradication campaign consisted of live attenuated 
vaccinia virus, and as late as 2004, enough was still available to immunize a population 
as large as that of the USA (Birmingham & Kenyon, 2001). Following vaccination, the 
virus would go through a few replication cycles, before being cleared by the immune 
system. This vaccine was highly effective in immunizing individual against not only 
smallpox, but because of their antigenic relatedness, it conferred protection against all 
other orthopoxvirus infections as welL 
However, the severity of post-vaccination complications (such as encephalitis and 
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early as 1972, before smallpox was globally eradicated (reviewed in Lofquist et aI., 
2003). 
Since the late 1980's, we were faced with a very different scenario: the threat of a serious 
natural orthopoxvirus infection was comparatively almost non-existent; therefore, post­
vaccination side effects of such magnitude would have been even less acceptable. 
Secondly, the emergence of immune-deficient individuals either due to the effects of 
HIVIAIDS (acquired immune deficiency syndrome) or solid-organ recipients has limited 
the use of live-virus vaccines in that population bracket. Therefore the only alternative 
available to this rapidly growing group of individuals, especially in the African continent, 
would be the use ofan effective therapeutic agent. 
Agents such as thiosemicarbazones (previously marketed under the brand name 
Marboran®) have proved its effectiveness in the clinical setting in large-scale treatment of 
serious poxvirus infections (reviewed in Bauer, 1969). These classes of agents were first 
reported in the 40's and were conservatively used during the smallpox epidemic in the 
following decades. However, although effective thiosemicarbazones caused serious 
vomiting following ingestion, possibly due to the high dosages required for effective 
therapy (>200 mg/kg). In addition, there was formation ofa toxic metabolite. 
Moreover, it had to be administered during the prodromal phase of infection, as it proved 
to be ineffective at later stages. However, these side effects and inconveniences were 
acceptable as a therapeutic agent in the face ofa potentially deadly poxvirus infection. 
In today's clinical management ofmostly non-lethal poxvirus infections, such side effects 
may not be tolerated 
More recently, a novel drug consisting of the nucleoside analogue cidofovir (Vistide®) 
was approved for the treatment of the herpes virus cytomegalovirus (CMV) infections in 
immunocompromised individuals. It has proved to be a potent in vitro inhibitor of all 
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proved to be effective in the treatment of certain opportunistic poxvirus infections in 
patients with HIV / AIDS. The drug only had to be administered once a week, which made 
it very promising for poxvirus therapy. However, its dose~dependent nephrotoxicity and 
the need to use the intravenous route for administration sparked a renewed search for less 
toxic and more effective agents that could be administered orally. 
Once again, this search turned to the kingdom of plants. Many therapeutic agents in 
current clinical use were obtained from this source, from morphine to cancer-fighting 
agents such as toxol (reviewed in Ming et al., 2003). Furthermore, plants have been the 
primary source and very often the only source of therapeutic agents since medieval times. 
A wealth of knowledge regarding plants and their healing properties has been 
accumulated over millennia. This knowledge extends beyond therapeutic value to include 
in some instances, the side effects, and precautions regarding their use. In light of this, 
many medicinal plants were considered safe by virtue of the time that they have been 
administered in the human population as well as knowledge gained during this period. 
Many plant extracts have proved effective in neutralizing a range of viruses from herpes 
simplex to HIV (reviewed in Jassim & Naji, 2003). However, the effectiveness of these 
medicinal plants has rarely been proven against poxviruses. Following the eradication of 
smallpox, the remainders of the poxviruses were not considered clinically significant 
pathogens for a few decades. Nevertheless, seed extracts from Musa superba and Ensete 
superbum as well as the leaves of Melia azadericta have been shown to have strong anti­
vaccinia and anti-variola activity (Pendse & Lyengar, 1967; Dutta et al., 1968 and Rao et 
al., 1969). 
In this study the anti-vaccinia virus, properties of SECOMET V (the reference name of a 
plant extract produced in a bioreactor from primary stem cells) were analyzed. The 
extract prevented in vitro infection of BSC-l cells by the attenuated VV strain VGK5 
(Kotwal et aI., 1989). The extract acted on cell-free virus particles as opposed to 
interfering with viral replication in infected cells, like most anti-poxvirus agents reported 
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could be neutralized with bovine serum albumin (BSA), a strategy that could be applied 
to purify the active agents. The data also indicated that the antiviral activity of 
SECOMET V was due to the presence of at least 2 agents that could be fractionated via 
HPLC and TLC. 
This extract has been used in folklore medicine, either by ingestion or as an ointment, to 
treat a range of maladies, and is still currently in use. The anecdotal evidence suggests 
that its ~oral bioavailability may be sufficiently high for therapeutic purposes, and could 
probably be used topically. 
1.2 - Vaccinia virus: a molecular biology perspective 
1.2.1 - Classification 
The family Poxviridae is subdivided into two sub-families depending on the host range 
(Francki et al., 1991). VV belongs to the Chordopoxvirinae sub-family of viruses, which 
infects vertebrates. This subfamily comprises 8 genera, of which VV belongs to the 
Orthopoxvirus genus together with 10 other members, named after their respective hosts: 
buffalopox, camelpox, cowpox, ectromelia (vaccinia sub-species), monkeypox, 
raccoonpox, skunkpox, Uasin Gishu (African horse pox), variola and volepox. 
Furthermore, all members of this genus share similar morphology and host range as well 
as genetic and antigenic relatedness. 
In spite of the fact that the natural host ofVV has to date not been identified (reviewed in 
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1.2.2 - Structure 
Poxviruses were the largest of the known mammalian viruses. Their morphology varies 
according to the preparation method, and four types of virions were readily 
distinguishable, namely: intracellular mature virions (IMV), intracellular enveloped 
virions (IEV), cell-associated enveloped virus (CEV), and the extracellular enveloped 
virions (EEV) (Schmelz et al., 1994). 
The IMV is fully infectious and was the most common form of VV used in the research 
arena. It was a large, brick-shaped structure, 350 x 270 nm, when observed under 
cryoelectron microscopy (Dubochet et al., 1994). Three different regions were visible, 
consisting of the external membrane, lateral bodies, and the dumbbell-shaped core 
(Figure 1.1). Furthermore, Easterbrook (1966) showed that the membrane surrounding 
the core consists of cylinder-shaped subunits, 10 nm in length and 5 nm in width and an 
inner layer ofequal size. 
The virions also packaged many enzymes and factors, and up to 16 have been reported to 
date (reviewed in Moss, 2002). Most were enzymes involved in DNA synthesis and post­
transcription modification such as polyadenylation, capping, and methylation. In fact, this 
system was so complete, that infectious virions were capable of carrying out in vitro 
transcription and processing ofmRNAs (Munyon et al., 1967). 
Chemically, VV virions consisted mainly of proteins (90 %, including glycosidic 
residues), lipids (5 %) and DNA (3,2 %) as well as RNA (Roening and Holowczak, 1974) 
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Figure 1.1: Cryo-EM of positively stained, reduced IMV. Three structural features were 





1.2.3 - Genome Organization 
Poxviruses were classified as type I viruses, in that they had double-stranded DNA 
genomes, ranging between 130-230 Kbp in size, and around 180 Kbp for VV (Goebel et 
aI., 1990). 
The genome was linear and had identical, inverted terminal repeats (lTR) at both ends, 
containing an A+T rich, incompletely base-paired, flip-flop loops that connected both 
strands (Baroudy BM et al., 1982) (Figure 1.2). 
The genome could be fragment into 3 distinct regions, namely: the terminal loop; the 
variable end-regions, which playa role in pathogen-host interaction; and the conserved 
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One hundred open reading frames (ORFs) have been identified to date encoding both 
structural and enzymatic proteins. 
An interesting feature of the poxviridae family regarding the genome organization was 
that their ORFs were largely non-overlapping. This could have been attributed to the 
large size of their genome which eliminated the need for extensive overlapping, a 
common feature in most virus families. 
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Figure 1.2: Schematic representation of the genomic organization ofVV. The terminal loops were 
10 Kbp in size and contains inverted terminal repeats. The main structural and functional proteins 
were encoded in the central region and are highly conserved throughout the genus 
(www.comellcollege.edu). 
1.2.4 - Gene Expression 
Gene expression in VV could be temporarily subdivided into 3 stages (Baldick and Moss, 
1993): early stage, beginning 20 min post infection, reaching a maximum after about 90 
min; intermediate stage mRNAs could be detected once early gene expression peaks, 
increasing very rapidly for 30 min, and decreasing just as fast. Late stage gene products 
were expressed at the time of peak of the intermediate gene products, reaching a 
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Early-stage gene products included proteins involved in DNA replication (Jones and 
Moss, 1984 and Lee and Niles, 1988), nucleotide biosynthesis (Hruby and Ball, 1982 and 
Smith et ai., 1989), immuno-modulation (reviewed in Kotwal, 2000), and intermediate 
gene transcription. About half of the virus genome was translated at this stage, before 
DNA replication (Oda and Joklik, 1967). 
Intermediate and late gene transcripts were expressed after replication and were involved 
in virion morphogenesis and assembly (reviewed in Broyles, 2003). 
1.2.5 - Vaccinia virus life cycle 
The life cycle of orthopoxviruses is the most complex of all mammalian viruses known to 
date. In light of this, it is not surprising that many gaps exist in our knowledge of VV 
replication. Depicted below is an oversimplified schematic representation of the major 
steps in the life cycle of VV as well as the sites of action of the various agents reviewed 










11 Chapter 1: Literature review 







~ ... IMP dehydrogenase inhibitors; OMP decarboxylase &® Early transcripttonr--- CTP synthetase inhibitors,' SAH hydrolase inhibitors 
~ 
fi\ v'rat rcati r--- Glycyrriza glabra?; A.cyclic nucleoside phosphonates,' 
\.:J 1 rer 1 on Thymidylate synthase inhibitors 
(!) Intennediate transcription r--- SAN hydrolase inhibitors 
~ 
® Late transcription r--- Thiosemicarbazones,' SAN hydrolase inhibitors 
~ 
® Assembly & envelopment 
~ . 
@ Release orland infection of neighbouring cells 
Figure 1.3: Schematic representation of W life cycle and drug targeting sites. Vaccinia virion 
attaches to the host cell via surface receptors (I), It then enters the cell (2), is internalised (3) and 
loses the envelope releasing the core into the cytoplasm (4). Early mRNAs are transcribed and 
translated. Early mRNs transcribe intermediate transcription factors as well as secretory growth 
factors and immunomodulatory proteins (5). DNA replication marks the beginning of the 
intermediate stage (6). Intermediate gene products are transcribed with the aid of the host's 
nuclear factors and translated into late transcription factors (7). These late transcription factors 
participate in the expression of structural proteins as well as transcription factors for early gene 
expression, which will be incorporated into the mature virion (8). Assembly begins in the Golgi 
apparatus with the formation of scattered membrane intermediates, giving rise to the immature 
virion (9). Maturation resulted in either the release of virions following cell lysis or infection of 
neighbouring cells from the host cell, without having to be released into the extracellular milieu 
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1.3 - Known Plants with Anti-Poxvirus Activity 
The use of medicinal plants to prevent and/or treat poxvirus infections more specifically 
smallpox, was widespread across the world. The advent of an effective vaccine against 
these deadly pathogens greatly reduced the interest in traditional medicinal plants, 
particularly with the advent of the global eradication of smallpox. However, work was 
nonetheless undertaken during mostly the last 2 decades of the epidemic to authenticate 
and characterize the anti-poxvirus properties ofmedicinal plants in folklore medicine. 
In light of this, a review of the very limited studies that where published regarding the 
subject at hand was undertaken below. 
1.3.1 - Ensete superbum (the seeds ofBanakadali) 
The anti-variola properties of this plant were first brought to the attention of the medical 
community in 1933 by a Portuguese doctor stationed in the former Portuguese colony of 
Goa, India (Pendse and Lyengar, 1967). The seeds were subsequently used in the 
Infectious Disease Hospital in Bombay, greatly decreasing smallpox-associated morbidity 
and mortality. 
However, the results obtained from one the first published studies using rabbits, did not 
reflect the results obtained by the Infectious Disease Hospital in Bombay nearly two 
decades earlier (Pendse and Lyengar, 1967). In a non·lethal model, rabbits received orally 
100, 500 or 1000 mglkg of a powdered solution resuspended in water for three days 
before infection and for four days post-infection. The effectiveness of the extract was 
measured as a function of the degree of localized skin scarification in control, untreated 
animals against treated. The temperature of both groups was also monitored, twice daily. 
However, no difference between control and test rabbits was observed. 
More encouraging results were obtained almost in parallel by a different group, in a much 
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more chemically purified fractions of the starting material of these seeds, they 
demonstrated that each fraction was decreasingly capable of inhibiting a virus titer of 103 
pfulml in ovo at a dose ranging from 0,9 J,Lg to 0,01 J,Lg. The highest particle-forming units 
(PFU) inhibition was 96,25 % for the most crude :fraction and down to 55 % for the most 
:fractionated one. VV and variola showed almost identical susceptibility to the fractions 
tested. Furthermore, it was observed that the extracts disrupted cell free-virus particles 
rather then interfering with the downstream events following adsorption (Figure 1.3, step 
1). For this reaso~ the extract fractions were incubated with the virus for 1 h prior to 
infecting the chorioallantoic membrane ofembryonated hen's eggs. 
The same group provided even more convincing in vivo evidence. Mice where either 
administered an oral solution containing 28 mg 6 h prior to virus challenge or 14 mg 24 
and 180 h post-infection respectively. It was observed that there was a survival rate of 96 
% in the pre-challenge treated mice and an almost equally high survival rate in mice 
treated post-infection (ranging from 85 to 95 %). 
Again, as in the results obtained in OVO, the least pure of the fractions was the most 
active, but the difference was not as accentuated. However, once the dosage was doubled 
(28 mg), there was almost no difference in survival rates across the animals treated with 
the different fractions, 120 h post-infection. 
The work described illustrated that the seeds of Banakadali were indeed active against 
poxviruses not only in ovo but also in vivo, while showing no toxic effect at therapeutic 
dosages. 
1.3.2 - Melia azaderictD (the leaves o/the Margosa tree) 
Yet another medicinal plant used in Indian folklore medicine, not only to treat poxvirus­
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Rao et al. (1969) demonstrated that 0,1 ml ofa 10 % (lfJ mg) solution of the leaves of the 
Margosa tree effectively reduced the number of PFU by 2 logs, when tested against a 
virus titer of 106 p:fu/ml of VV in vitro. Furthermore, they also showed that the leaf 
extract was only active if incubated with the virus before infection. This cle~ly suggested 
that the antiviral properties were due to a direct effect on cell-free virus particles and not 
by interfering with the post-infection events, much like the seeds of Banakadali (Figure 
1.3, step 1). 
Even more compelling evidence originated from the work carried out in vivo, where a 3· 
log drop in virus titters was observed for VV and two logs for variola virus. It was also 
observed that the virucidal effects of the leafextract were dose-dependent. 
When the work was extended to primates, more specifically the Indian Bonnet monkey 
(Macacus radiata), it was clear that the leaf extract had a positive effect in the normal 
course of infection. The untreated animals developed localized ulceration and necrosis 
which lasted for 32 days, whereas the treated animals a much milder ulceration and minor 
necrosis, lasting for only 12 days. 
This was another plant that clearly showed therapeutic potential, but was not exploited in 
large scale. 
1.3.3 - Glvcrrriza glabra (the roots) 
The active constituent in this case was known to be glycyrrhizic acid, and an array of 
viruses were tested, but VV was the only member of the poxvirus family. A pure, 
commercially available preparation was made at a concentration of 8 mM (Pompei et al., 
1979). It was observed that the addition of glycyrrhizic acid immediately post infection 
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Based on the$e data, the investigators speculated that the virucidal properties of 
glycyrrhizic acid might be due to the interaction with sensitive virus proteins, during the 
replication of W (Figure 1.3, step 6). No cytotoxicity was observed at the working 
dosages. 
However, no animal work was undertaken and the study was very limited. Nonetheless, it 
was shown that a plant metabolite was an effective, non-specific antiviral agent, which 
could have been further exploited for therapeutic potential. 
1.4 • Vaccinia Virus Inhibitors of Known Structure and Mode of 
Action 
The complex life cycle of orthopoxviruses presented many virus-specific drug-targeting 
sites from entry (Figure 3, step 1) to maturation inhibitors (Figure 3, step 10). 
In this section, W inhibitors were reviewed and grouped according to structure and 
pathways inhibited. Furthermore, their in vitro and in vivo efficacies were described as 
well as effectiveness and side effects in the clinical setting where applicable. 
1.4.1 - Acyclic Nucleoside Phosphonales 
Cidofovir [(S)-I-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine] [(S)-HPMPC] 
belongs to this class of inhibitors. It was commercially available under the brand name 
Vistide® since the late 1990's, and was approved to treat CMV retinitis in AIDS patients. 
The activity of cidofovir against a broad spectrum of DNA viruses (De Clercq et at., 
1986) and its anti-vaccinia virus activity was first described over a decade ago (De Clercq 
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The mode of action of this antiviral was determined by studies carried out in CMV, and it 
was observed that it inhibited viral DNA synthesis 1000·fold stronger than cellular DNA 
synthesis (Neyts et al., 1990). It was an analogue of the nucleotide cytosine and causes 
chain-termination upon incorporation in a growing DNA strand (Figure 1.3, step 6). 
Cidofovir proved very effective in neutralizing VV in vitro (ECso of 5 Ilglml). 
Furthermore, its efficacy against orthopoxvirus infections was further strengthen when in 
vivo work was carried out; severe combined immune deficiency (SCID) mice survived 
ten-fold longer when cidofovir was administered, subcutaneously (s.c.) at dosages 
ranging from 1 mg/kglday for 5 days to 20 mg/kg, twice a week, than untreated mice 
(Neyts et al.,1993). Furthermore, when a single large dose (l00 mg/kg) was administered 
0, 2 and 4 days post-infection via the same route, cidofovir was fou d to protect mice 
against a lethal inoculation ofcowpox (Bray et al., 2000). 
In a parallel study, Smee et al. (2000) showed that a single intranasal dose (10, 20 and 40 
mg/kg) of cidofovir conferred 90-100% protection against a lethal dose of cowpox virus 
in mice, when administered 24 h after lethal aerosol or intranasal virus challenge. 
The superiority of aerosol-delivered cidofovir against other delivery systems was :furtl)er 
strengthened in a study where, mice where inoculated with a lethal dose of aerosolized 
cowpox and followed by treatment with 0,5-5 mg/kg of aerosolized cidofovir (Bray et al., 
2002). The survival rates were much higher, and the virus titers were much lower than in 
those treated with 25 and 100 mg/kg ofcidofovir delivered subcutaneously. 
More recently, Chad and colleagues (2003) reported that aerosol delivery of cidofovir in 
mice resulted in longer retention times of the drug in the lungs, and a marked decreased 
concentration in the kidneys. Nearly all mice treated with a single dose two days prior 
and two days post infection survived. 
In an attempt to improve cidofovir's oral bioavailability, a novel series of analogs were 
synthesized by esterification with long-chain alkoxyalkanols. Keith et al (2004) showed 
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(ODE..cidofovir) were active in vitro, against VV with an ECso of 0,52 and 42 IlM 
respectively. The addition of the ester moiety effectively increased the bioavailability of 
cidofovir by between 88 and 97 % (Ciesla et al., 2003) as opposed to that of 5 % for 
cidofovir alone (Wachsman et al., 1997). 
When the efficacy of these lipid esters was tested in mice, it was observed that their 
effectiveness was similar to that of parentally administered cidofovir (Quenelle et al., 
2004). Furthennore, it was observed that the pharmacokinetics of the lipid esters was 
almost identical to that of cidofovir alone, in that therapeutic levels in critical organs 
(lung, liver and kidney) persisted for 72 h after a single oral administration of 10 mglkg. 
This equated to a twice weekly oral dose. 
In the clinical setting however, only two types of poxvirus have been treated successfully 
with cidofovir (De Clercq, 2002 review), namely Ecthyma ;nfectiosum (orf) by topical 
application (Geerinck et al., 2001 and MacCabe et al., 2003) and Molluscum 
contagiosum both by local and parental route (Meadows et ai., 1997; Davies et al., 1999; 
Zabawski et al., 1999; Ibara et al., 2000; Toto et al., 2000 and Baxter and Highet, 2004). 
However, in spite of being a very effective anti-orthopoxvirus agent, there are two 
drawbacks: the dose-dependent nephrotoxicity of this antiviral restricted its use in 
disseminated infections (maximum of 5 mglkg/day) (Lalezari et al.~ 1995). This was 
potentially a very serious setback, since smallpox and monkeypox caused systemic 
infections rather than localized (as was the case with the other two poxviruses above 
described). 
Moreover, cidofovir~resistant strains ofcowpox and vaccinia have been generated in vitro 
(Smee et af., 2002). These resistant strains although less fit, were nearly as lethal as the 
wild-type strain. It was observed that mice infected with cidofovir-resistant cowpox did 
not respond to cidofovir treatment and succumbed merely 36 hours later than the control, 
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Cidofovir was the most likely and possibly the sole agent that would have been used in 
the clinical setting for the treatment oforthopoxvirus infections. 
1.4.2 - Thiosemicarbazones 
The frrst antiviral agents discovered belonged to this family of substances. Its anti­
vaccinia virus activity was frrst reported over 50 years ago by Hamre et al. (1950) using 
chick embryos and mice as hosts. They also reported a high ECso of less than one J.1g1ml 
in human cervical epithelial cells (HeLa). However, these values are not in agreement 
with those obtained by Baker et al. (2003). They reported an ECso between 45,8 and 52,0 
J.1g1ml for Vero and LLC-MK2 cell lines respectively. 
The search for the most active thiosemicarbazones culminated with the discovery of the 
I-methyl derivative (Thompson et al., 1953 and Bauer, 1954), which resulted in the first 
clinical trial 6 years later (reviewed in Bauer, 1960). 
The antiviral was marketed under the brand name Marboran®, and several field trials 
indicated that it was effective enough agent to justify its use in the prodromal treatment, 
and prophylaxis of smallpox infections (Bauer et al., 1963; Bauer et al., 1969 and Heiner 
et al., 1971). However, the mode of action of this antiviral was only elucidated 5 years 
after being approved for clinical trials (Woodson et al., 1965). Through a series of elegant 
experiments, Woodson et al. (1965) demonstrated that thiosemicarbazones exerted its 
antiviral effect by interfering with the transcription of late mRNA's, thereby inhibiting 
virion morphogenesis and assembly (Figure 1.3, step 8). 
As effective as methisazone was against variola, its side effects of extreme vomiting and 
diarrhea restricted its use in prophylaxis, even as far back as the 1960's (Bauer et al., 
1963). The other downside was the large dosages (200 mglkg first dose, 800 mglkg 
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Methisazone was nonetheless widely used, and was the only antiviral, which has proved 
effective in the clinical setting, for the treatment ofpoxvirus infections. 
1.4.3 - IMP dehydrogenase inhibitors 
Fluoroimidazoles, EICAR (5-ethynyl-l-~-D-ribofuranosylimidazole-4-carboxamide), 
tiazofurin (2-~-D-ribofuranosylthiazole-4-carboxamide), selenazole (2-f3-D­
ribofuranosylselenazole-4-carboxamide) and ribavirin (1-f3-D-ribofuranosyl-1 ,2,4­
triazole-3-carboxamide) all belong to this class of agents (reviewed in De Clercq, 2001). 
They were nucleoside analogues that acted by blocking the conversion of IMP to 
xanthylate (XMP), a crucial event in the synthesis ofpurine mononucleotides (Streeter et 
ai., 1973). This in turn, led to the depletion of GTP and dGTP pools, thereby interfering 
with the production ofearly mRNA transcripts (Figure 1.3, step 5). 
Ribavirin (1 ~~-D-ribofuranosyl-l ,2,4-triazole-3-carboxamide) was chemically 
synthesized in 1972 (Witkowski et al., 1972) and its in vitro (Witkowski et al., 1973; 
Huffman JH et al., 1973 and Katz et al., 1976) and in vivo (Sidwell et al., 1972) activity 
against a broad range of viruses including poxviruses was immediately established. 
Sidwell et al. showed that a 20 % solution of Ribavirin (Virazole) applied topically twice 
daily for 15 days to the tail, inhibited the development of vaccinia virus lesions in New 
Zealand albino rabbits. The same group also showed that the concentration of drug 
required to kill 50 % of the animals was 2000 mglkg when given orally. EICAR, a 
derivative of Virazole, exhibited a similar effect in mice inoculated intravenously (in the 
tail vein), when treated with 25 mg/k/day intraperitoneal for 5 days (De Clercq et al., 
1991). 
To date; the most effective anti-vaccinia antiviral of the IMP dehydrogenase inhibitors is 
EICAR, being 100-fold more active than Ribavirin in PRK cells (ECso of 0,2 ~glml Vs 
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J.1g1ml), tiazofurim (ECso of 45J.1g1ml) and selenazole (ECso of 3 J.1g1ml) were significantly 
less active than EICAR (De Clercq et al., 1976 and Kirsi et al., 1983). 
Since this group of antivirals has not been used in the clinical setting, nor have any 
human trials ever been carried out, its efficacy and side effects were not known. 
1.4.4 - OMP decarboxylaselCTP synthetase inhibitors 
Both agents worked by blocking the production of cytidine (CTP) by either interfering 
with the synthesis of uridylate (UMP) from OMP (OMP decarboxylase inhibitors) or 
blocking the conversion of UTP to CTP (CTP synthetase inhibitors) hence suppressing 
RNA synthesis (Figure 1.3, step 5). 
The prototype for the OMP decarboxylase class of inhibitors was Pyrazofurin, which was 
also the most active (Petrie et al., 1986). It has shown potent activity against VV (ECso of 
0,1 Ilglml) in PKR cells, even more so than the IMP dehydrogenase inhibitor Ribavirin. 
In fact, this agent appeared similar to EICAR in activity, yet its toxicity index in tissue 
culture was 1 OOO-foid higher than the ECso. 
In spite of this, the use of Pyrazofurim in the clinical setting was never pursued as 
aggressively as other antiviral agents. Furthermore, no literature could be found detailing 
the efficacy of Pyrazofurin in in vivo aninial models. 
Regarding the CTP synthetase inhibitors, Carbodine (cyclopentyl cytosine [C·CydD as 
well as cyclopentenyl cytosine (the most active of the two) have demonstrated strong 
anti-vaccinia virus activity (De Clercq et ai., 1990 and De Clercq et ai., 1991). With an 
ECso of 0,04 J.1g1ml and host cell toxicity of 400 J.1g1ml in PRK cells, cyclopentenyl 
cytosine appeared to be one of the most active (20-fold greater inhibition than EICAR) as 
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likely that because these inhibitors target host cell enzymes rather than viral, very little 
interest has been paid to this class ofagents. 
1.4.5 - Thymidylate synthase inhibitors 
This class ofantivirals was also known as 5-substituted 2'-deoxyuridines by virtue of the 
fact that they only differ at the 5' position. About 16 substitutions have been made at the 
5'position, all ofwhich proved active against VV (reviewed in De Clercq, 2001). 
Inhibition of Thymidylate synthase resulted in inefficient nucleic acid synthesis (Figure 
1.3, step 6), due to the depletion of dTTP polls brought about by the inhibition of the 
conversion ofdUMP to dTMP (De Clercq et al., 1981). 
The two most active forms of Thymidylate synthase inhibitors were achieved when 
fluorine and bromine were introduced in the 5'position. The ICso in PRK cells was 0,1 
J..I.glml for both substitutions (De Clercq, 1980). However, it was the iodo substitution (5­
iodo-dUrd) that was extensively used in animal models. 
In 1967, Boyle et al. used the tail-lesion model to test the efficacy of 5·iodo-dUrd. In 
their work, mice were infected intravenously (Lv) with VV, followed by subcutaneous 
(s.c) administration of 5-iodo-dUrd at a dose of 100 mgld for 7 days. The test-substance 
was successful in curJ?ing the formation oftail lesions. 
Further work was carried out by Hyndiuk et al. (1976 a) which demonstrated that topical 
solution of 0,1% of iododeoxyuridine when applied at 2 hour intervals for a total of 8 
applications, 36 h post-infection, effectively suppressed keratitis (eye infection). The 
same group later showed that similar results could be obtained by using a 0,5% solution 
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In the same year, the efficacy of the iodo, methyl and thiocyano derivatives were tested in 
the same tail-lesion model (De Clercq et al., 1976). Successful inhibition of tail lesion 
formation was obtained when the substances were delivered intraperitoneally (doses 
ranged from 4, 20 and 100 mglkg/d) for four days, starting immediately post-infection. 
No furUter in vivo work has been carried out using any of the 16 known derivatives of 
deoxyuridine up to the end of 2004. In light of the above evidence, these compounds 
merit that further work should be carried out to fully exploit their potential as effective 
therapeutic agents. 
1.4.6 - SAD hydrolase inhibitors 
These inhibitors were adenosine analogs that blocked the cleavage of s­
adenosylhomocysteine (SAH) into homocysteine and adenosine, its two components 
(reviewed in Borchardt, 1980). Adenosine Was further converted into inosine, adenine, or 
AMP. When this process was blocked, S-adenosylmethionine dependent methylations 
were inhibited thus inhibiting the maturation of VV mRNAs (such as 5'-capping; Figure 
1.3, step 5). 
As many as 24 such inhibitors have been described to date (reviewed in De Clercq, 
2001), of which those belonging to the class of the carbocyclic adenosine analogues 
proved to be the most effective, with ECso less than 0.05 f.tg/ml. Equally strong were 
Neplanocin A (De Clercq, 1980), 3-Deazaneplanocin A (Tseng et al., 1989), (-)-5'­
Noraristomycin (Siddiqi et aI., 1994) and (R)-6'-C-Methylneplanocin A (Shuto et al., 
1992) in primary human embryonic skin-muscle fibroblasts in stationary culture (E6SM) 
as well as PKR. Furthermore, the cytotoxic dose was >20,000 fold higher than the ECso, a 
very low value. 
No further literature was found on work carried out in animal models to demonstrate the 
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1.4.7- Po/yanionic Substances 
It appeared that these agents exerted their antiviral activity by coating cell-free virus 
particles and blocking the sites required for interaction with cell-surface receptors 
(Hosoya et at., 1991; Figure 1.3, step 1). These substances included sulphated 
polysaccharides (which are mostly extracted from seaweeds) such as poly-L-Iysines and 
poly-D-lysines, dextran sulphate and pentosan polysulfate to name a few. 
These agents were known to have broad-range antiviral activity in vitro against 
enveloped viruses (Baba et at.~ 1988; Witvrouw et at., 1994 and De Clercq et al., 2001). 
Furthermore, there was a direct correlation between molecular weight (MW) and 
inhibition. The highest inhibition achieved with poly-L-Iysine was 40 J!glml and higher 
for poly-D-Iysin~ of identical MW (20 000) in human embryonic skin muscle fibroblasts 
(ESM), which Was the CCso, indicating a weak and toxic antiviraL 
The most effective of the polycations was dextran sulphate. The CCso was 10-fold greater 
than the ECso (20 J!glml) in the ESM cell line (Hosoya et at., 1991). 
A literature search on the effectiveness of these agents in animal models yielded no 
results. 
1.4.8 - Miscellaneous Antivirals 
Rifampin, a tuberculostatic agent used in front-line therapy of tuberculosis, has been 
reported to have anti-VV activity (Subak-Sharpe et at., 1969). However, a high 
concentration of the drug (100 J!glml) was required to inhibit viral replication, which 
immediately ruled out its use in the clinical setting due to toxicity. 
Two other antibiotics reported to have similar in vitro activity to that of rifampin were 
congocidine and distamycin A (Becker et at., 1972). Whereas the inhibition of poxvirus 
replication brought about by rifampin and distamycin A was reversible (ECso of 100 
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Another antibiotic. this time a derivative of the macrolide antibiotic rifamycin, 
streptoviricin consisted of a mixture of five compounds related to rifamycin. Its anti­
vaccinia virus activity was almost negligible at the concentrations used (2 ~glml) 
(Quintrell and McAuslan. 1970). 
1.5 - Conclusion 
The renewed clinical interest in orthopoxviruses was brought about mostly due to the 
concern that it could be used as a bioweapon. However, emerging poxviruses such as 
monkeypox should not be ignored as a potential threat to public health. 
It was clear that vaccination with the existing vaccines or even novel vaccines was 
unrealistic and unnecessary. What was really needed were effective therapeutic agents 
that are well tolerated in immunocompromised patients that are already under severe 
stress due to the nature of the disease and accompanying therapy. 
It was also clear that we do not yet have such therapeutic agents, although cidofovir looks 
promising. However, the complexity of the poxvirus infectious cycle and the vast array of 
virus-specific enzymes. presented a large pool ofnovel and highly specific drug-targeting 
sites that could be explored in drug design as well as bio prospecting. 
However, poxvirus infections were still not significant enough to Warrant the attention of 
the big pharmaceutical and biotechnology enterprises. 
Dozens of therapeutic agents have been obtained directly from natural systems, 
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activity; therefore, it is very likely that many novel and clinically effective agents are yet 
to be discovered. 
However, there was rapidly growing need for an effective and inexpensive therapeutic 
agent with tolerable side effects that could used to minimize the discomfort and severity 
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1.6 - Scope of the project 
The goals of this project were to characterize the anti-vaccinia virus properties of 
SECOMET V by: 
1. 	 Establishing the anti-vaccinia virus activity ofthe extract; 
2. 	 Monitoring its cytotoxicity effect on BSC-I cells and determine a working dose; 
3. 	 Determining at which stage in the replication cycle did the antiviral interfered 
with; 
4. 	 Asserting if the antiviral was taken up by the host cells by studying its impact on 
cell-associated virus particles; 
5. 	 Establish parameters for future fractionation and purification of the active agents 
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Chapter Two II 
2.0 - MATERIALS AND METHODS 
2.1 - BSC-1 tissue culture (Protocols adapted from the Sigma­
Aldrich® hand book Fundamental techniques in cell culture). 
2.1.1- Maintenance ofthe cell line 
Cells were maintained in three flasks of different surface-areas (25, 75 and 150 cnl 
respectively, Corning Inc, Coming, NY, USA) at 37°C, 5% C02 containing complete 
minimal essential medium (CMEM; Highveld Biological, Lyndhurst, SA) and enriched 
with 10% fetal calf serum (FCS, same manufacturer). Antibiotics were added at a 
concentration of 500 Jlg/ml penicillin and streptomycin, and 250 ng/ml fungizone 
(Highveld Biological, Lyndhurst, SA), supplied as a triple mixture concentrated 100-fold. 
The size of the flask varied depending on the number of cells required. If no cells were 
needed, then the smaller 25 cm2 flask was used. Cell confluency in a 150 cm2 flask was 
reached at a total number of 2x107, whereas in a 25 cm2 a total of 3x106 cells were 
required to cover the growth area. 
To assess the degree of cOnfluency as well as to ensure that there were no contaminants, 
the cell monolayer was observed under an inverted microscope at x20 magnification. 
Only once the monolayer was 100% confluent were the cells sub-cultured. This 
procedure was carried out by discarding the overlay medium followed by rinsing cell 
monolayer twice, with equal volumes ofpre-warmed (at 37°C in a water bath) phosphate 
buffer solution (PBS, Sigma®, ST Louis, MO, USA), pH 7.2 to remove all traces of 
growth media and anti-trypsin factors that could interfere with the trypsin treatment. 
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depending on the surface area of the flask) for 10 min to detach the cells from the bottom 
ofthe flask. 
Once the cells were loose, the flask was tapped gently to remove any cells which were 
still attached. To ensure that all cell-clumps were broken, a 2 ml disposable pipette was 
used to aspirate the cell-suspension up and down a few times. 
If the cells were not used for further work, they were diluted 20-fold and re-seeded either 
in the same flask (all flasks were re-seeded no more than 3 times) or into a new flask. 
2.1.2 - Incubation ofBSC-1 cells 
BSC-l cells were incubated in a C02 incubator (5 %), which aided in maintaining the 
physiological pH of the culture medium, preventing it from turning acidic as waste 
products of cellular metabolism accumulate. The temperature was kept constant at 37°C 
and the humidity was also constant at 90 %. 
2.1.3 - Cell quantifICation 
Adherent cells were detached via trypsin treatment (section 2.1.1 in this chapter) and 
were gently aspired a few times to further break up any clumps. This was followed by 
removing a 20 ,.d aliquot of suspended cells and incubating it with an equal volume of a 
0,2 % solution of trypan blue (Sigma, ST Louis, Mo, USA) for 5 min at rlt, in a 
microcentrifuge tube. 
In the meantime, the coverslip of the haemocytometer (counting chamber, improved 
Neubauer®, Balu Brand, Germany) was moistened with water and gently swerved over 
the chamber until Newton's refraction rings were formed. The cell/dye suspension was 
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the swface area of the chamber, without flooding it thereby minimizing overestimating 
the number ofcells). The cell count was then carried out under a light microscope using a 
x20 magnification. 
The number of viable and non-viable cells was quantified by counting the cells in all 8 
quadrants (each cell in a clump was counted). Dead cells stained blue, live cells did not 
stain. The total number of cells was then calculated by multiplying the correction factor 
of the chamber (104) by the average number ofcells counted and by the dilution factor (2) 
to obtain the total concentration of cells/mI. Percentage cell viability was then calculated 
by dividing the average number ofviable cells by the total number ofcells and multiplied 
by lOO. 
2.1.4 - Cryopreservation 
For this purpose, adherent cells were cultured in a 150 cm2 tissue culture flask and Used 
at a confluency between 80 and 90 % to ensure to ensure that a healthy population of 
cells in the exponential growth phase was frozen. Once the cells were detached from the 
flask using trypsinlEDT A, a cell count was performed. A minimum viability of 90 % was 
required for cryopreservation. 
The remainder of the cells was then centrifuged in a Heraeus® Multifuge 3L-R (Kendro 
Laboratory Products, Ha au, Germany) at 100 g, 20°C for 5 min using a swinging-rotor 
bucket. After the supernatant was discarded, the cells were resuspended gently in 
cryoprotective media (Biowhittaker, Walkersville, Maryland, USA) containing 15% 
DMSO, at a density of2xlO6 cells/mI. The cell suspension was then aliquoted into 2 ml 
cryovials (Corning Inc, Corning, NY, USA) at a volume of 200 JII per vial. The vials 
were subsequently stored at -80 °C for,24 h and transferred thereafter to liquid nitrogen 
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2.1.5 - Resuscitation offrozen celIs 
The frozen cells were removed from the liquid nitrogen storage unit and immediately 

partially thawed in a water bath at 37°C until a small amount of ice was still present, to 

minimize DMSO toxicity, which was cytotoxic above 4 °C (if ice was still present it 

meant that the solution was still below 4°C). , 

The thawed cells were then transferred to four volumes of pre~warmed CMEM, 10% 

FCS, drop wise to dilute out the DMSO. The cells were then recovered by centrifugation 

as described above (section 2.1.3 in this chapter). Once the supernatant was decanted, the 

remaining cell pellet was resuspended in 5 m1 of growth media and transferred to a 25 

cm2tissue culture flask and placed in the C02 incubator for a period of24 h. 





2.1.6 - Seeding 6-well and 96-well tissue culture plates (Protocols adapted/rom Jonc1,J' 
et(lL,2000) 
Six-well tissue culture plates (Coming Inc, Coming, NY, USA) were seeded at a density 
of 106 cells/well in a total volume of2 m1 of CMEM, 10% FCS per well, whereas the 96­
well tissue culture plates (Coming Inc, Corning, NY; USA) were seeded at a density of 
2x 104 cells/well in a volume of 100 ill/welL Once the tissue-culture plates were seeded, 
they were transferred to the C02 incubator. The tissue culture plates were usedonly once 
the BSC-l mono layers were 100% confluent (2 to 3 days after seeding). 
2.1.7- Staining BSC-1 cells in tissue-culture pl4les 
Ten m1 of a 0,01 solution of crystal violet (SaarchemlSigma, Wadeville, Gauteng, SA) 
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fixating agent) prior to use. This was necessary not only because the crystal violet was 
suspended in water, which would lyse the cells but also because it was too concentrated, 
as observed by the formation ofa dark violet precipitate on stained cell monolayers. 
After the overlay medium was discarded from the culture plates containing BSC-1 cells, 
the crystal violet solution was added (20 Jlllwell for 96-well plates and 200 Jll/well for 6­
well plates) to the monolayer and incubated at room temperature for 1h in order to allow 
for the cells to take up the dye. Once the time elapsed, the remaining solution was 
removed and the cells stained violet .. 
2.2 - Making stock virus and titration (Adapted from Kotwal & 
Abrahams, 2004) 
2.2.1 - Virus propagation 
A tissue culture flask with a surface area of 150 cm2 containing a confluent monolayer of 
BSC-! cells was used. Prior to infection, most of the overlay medium was removed (but 
not discarded), leaving only enough to cover the monolayer to facilitate synchronous 
adsorption of the viral particles. Virus was then added to the monolayer at a multiplicity 
of infection (MOl) of 0.01 (1 pfu per 100 cells, for a total of 105 pfu). 
The virus was allowed to adsorb for 90 min, after which time the remainder of the 
medium was added back to the flask, and the now infected cells were further incubated 
for 24 h. The now virus-infected cells where harvested with the aid of a cell scraper 
(Coming Costar®, Cambridge, MA, USA) and resuspended in 5 ml of :PBS at r/t. 
The pfu were then released from inside the cells with 3 freeze (at -20 °C)-thaw (at 37°C) 
cycles. The resulting cell debris was removed by centrifugation at 1000 g for 10 min at 4 
°c in a swinging-rotor bucket. 
The virus laden supernatant was collected and subject to two 1 min sonication cycles at 










32 Chapter 2: Materials and methods 
release the virus aggregations. The sonication was carried out with the samples on ice, to 
prevent heat-induced virolysis of the cell-free pfu. 
2.2.2 - Virus titration: plaque assays 
A 6-well tissue culture plate containing a confluent monolayer of BSC-l cells was used. 
A volume of 20 tll of virus suspension was added to the first well. This was followed by 
2 100 fold serial dilutions and 3 lO-fold dilutions respectively, effectively diluting the 
virus suspension 10-9 fold. The infected cells were incubated for 48 h, after which time a 
clear cytopathic effect (CPE) was observed under an inverted microscope at a 
magnification of x20. After discarding the overlay media, the wells were individually 
stained with crystal violet solution. 
The titer was determined by counting the number of plaques in the lowest dilution that 
contained more than 10 but less than 100 plaques, and dividing it by the dilution factor 
(Le.: 10 plaques in the well corresponding to the 10-7 dilution indicates a titer of 10110.7= 
108 pfulml). 
2.2.3 - Serial dilution ofantiviral-treated virus in 96-well plates 
Sterile, flat-bottom tissue culture plates (Corning Costar®, NY, USA) without lids, were 
used. A volume of 30 tll of MEM, 10% FCS was added to row A, followed by 45 tl1 to 
all the remaining rows. After incubating the virus with the test substance, the suspension 
was transferred to row A, for a total volume of 50 tll (NOTE: the total volume of the 
virus/test substance mixture was fixed at 20 tll). 
Seven 10-fold serial dilutions were carried out, starting from row A, by transferring 5 tl1 
of virus-infected media from row A down to the last row H, from which 5 tl1 were 
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Following the serial dilution, the media was then transferred to a 96-well tissue culture 
plate, containing a confluent monolayer of BSC~1 cells, in the same order as that of the 
dilution plate. 
2.3 - Characterization of the antiviral properties of SECOMET V 
2.3.1- Determination ofdry weight 
Aim: To determine the dry weight of the plant material in order to standardize all further 
work accordingly. 
The plant extract was supplied dissolved in distilled water (dH20). The weighing process 
started by weighing 3 empty microcentrifuge tubes, and labeling them accordingly. The 
extract was then dispensed into each tube at a volume of 200 J.d/tube. The samples were 
then dried in a vacuum concentrator (Speedvac® SPD1l1V, ThermoSavant, Holbrook, 
NY, USA) at 80°C for 8 h. 
After drying, the samples were weighted and the dry weight of each was determined by 
subtracting the weight of the microcentrifuge/dry material by that of the microcentrifuge 
alone. Following this, a second identical drying cycle was carried out. If there was no 
variation in weight, the sample was assumed to be dry, and the dry weight of the material 
was then detennined as the average of the 3 samples. 
2.3.2 - Inhibition ofviral replication (adapted from Herndnde~-Corona et at, Z002) 
Aim: Investigation of the anti-VV activity of the extract and if such activity was linked to 
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Six~well tissue-culture plates containing BSC~1 cells were infected in triplicate, with a 
total of 102 pfu. The virus-infected plates were incubated for 90 min to allow for viral 
adsorption. Following the adsorption event, the overlay media was removed and the cell 
monolayers were washed twice with 1 ml of pre-warmed PBS to remove any unadsorbed 
viral particles (tips were never used more than once without being replaced). This was 
followed by the addition of 2 ml of fresh growth media, containing extract at a lethal but 
non-toxic concentration (100 Ilglml). The virus-infect cells were then incubated for 48 h. 
Wells were also infected with untreated virus, in triplicate. As a control for VV 
inactivation, virus at the same titer was incubated with the extract at a concentration of 
100 Ilglml for 60 s prior to infection. After 48 h, the cells were stained with crystal violet 
solution and scored for CPE. 
2.3.3 - Inhibition 0/adsorption (adopted/rom Hernandez-Corona et aL, 2002) 
Aim: To determine whether the virucidal effects of the extract were due to a direct 
disruption ofcell-free pfu, prior to infection. 
Virus at a titer of lOS pfu/ml in a volume of 10 III was incubated with an equal volume of 
extract (for a final concentration of 11 mglml) at room temperature for 60 s. The 
extract/virus suspension was then used to infect BSC-l cells, in triplicate, in 6-well 
plates. 
Following the two day incubation period the cells were stained with crystal violet 
solution and the number ofpfu was counted. 
2.3.4 -Cytotoxicity assay: CCso (Adapted/rom Kurokawa et aL, 1995). 
Aim: To establish a working dose as well as to quantify the cytotoxicity index of the 
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cytotoxicity assay measures the concentration of extract that reduces cell viability (BSC­
1) by 50 %, using the trypan-blue vital dye exclusion method. 

A 96-well plate containing a confluent monolayer of BSC-l cells was used. Decreasing 

volumes of the crude extract were tested, starting at 10 I.d (2200 ~g/m1) down to 1 ~l (220 

~g/ml) in 1 p.l increments. The lowest dilution used was 0,5 J.lI (11 0 ~g/ml). Following 

the addition of the extract, the cells were further incubated for 24 h. The overlay media 

was then removed, and the cell mono layers were washed 3 times with 1 00 ~l of pre­

warmed PBS. Following the PBS wash, the cells were subsequently rinsed once with 20 

~l of pre-warmed trypsin, to remove any remaining anti-trypsin factors. The cells were 





Once the cells were suspended, they were inspected under an inverted microscope to 

ensure that there were no cell aggregations that would interfere with the counting process. 

The cells were then stained with an equal volume of trypan blue under the inverted 

microscope at x20 magnification (section 2.1.3 in this chapter). 

Percentage cell viability was calculated from the following equation: 

no. dead cells (stained blue) x 100 

no. live cells (unstained) 

The CCso value was then calculated from a curve relating percent cell viability to the 
concentration oftest extract. 
2.3.5 -ECso assay (Adaptedfrom Joncz,y et at., 2000 and Yoosook et aI., 1999). 
Aim: This assay provided information regarding the strength of the antiviral activity of 
the extract as a whole. The ECso consists in the determination of the concentration of test 
substance that reduces plaque formation by 50%, and is the standardized value used to 
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A total of 10 serial two-fold dilutions of the crude extract were tested, carried out in 
sterile microcentrifuge tubes, using tissue-culture grade PBS as the solvent. The highest 
dilution was 11 mglml and the lowest 110 Ilglml. 
The test substance was then incubated with 10 III of VV at a titer of 108 pfulml for 60 s, 
in a final volume of 20 III in sterile 1,5 ml microcentrifuge tubes. All assays were carried 
out in triplicate. Controls included were: virus incubated with PBS and untreated virus. 
The infected plates were then incubated for 48 h and stained. The plaques in the 2nd 
lowest dilution that still produced plaques were counted. The percentage inhibition was 
then calculated using the following equation: 
No. surviving pfu x 100 
PBS-treated virus 
The ECso was then extrapolated from the curve relating the percentage inhibition (y-axis) 
to the concentration ofextract (x-axis). 
2.3.6 ~ Inactivation kinetics 
Aim: To study the relationship between the rate of plaque inhibition as a function of 
time. 
One hundred and twenty III of extract was incubated with an equal volume of W at a 
titer of 108 pfulml for a total time of 10 min, for a fmal concentration of extract of 1180 
mglml (the ECso). At 1 min intervals, 20 J-li of virus treated extract was taken and used to 
infect BSC-! cell monolayers in 96-well plates. Following 48 h of incubation, the 
rnonolayers were stained, and number of pfu was scored and plotted in a line graph 
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2.3.7 -Investigation ofinhibition ofcell to cell viral spread (Adapted from Kimiyasu et 
aL, 1992 and Jonc~ et aL, 2000) 
Aim: This experiment indicated whether or not the antiviral agents were taken up by the 
cell without losing its virucidal activity~ by measuring the number of surviving progeny 
virions. The assay was similar in principle to the one used to determine the ECso (section 
2.3.5 in this chapter) except that the maximum concentration did not exceed 500 Jig/ml. 
A 75 cm 2 tissue culture flask containing a confluent monolayer of BSC-l cells, was 
infected with W at a MOl of0.0 1 and incubated for 24 h. The overlay medium was then 
decanted and the monolayer was rinsed 3 times with 15 ml ofpre-warmed PBS to remove 
any cell-free virions. The cells were then suspended with the aid of2 ml of trypsin. After 
20 min, the now suspended cells were gently aspired a few times, to minimize cell­
clumping. The cells were visualized under an inverted microscope to ensure that there 
were no aggregations of cells. The cells were then recovered by low speed centrifugation 
at 100 g for 5 min at 20°C in a swinging rotor bucket. After the supernatant was 
discarded, the cells were resuspended in 1 ml of pre-warmed MEM and used 
immediately. The crude extract was diluted 9 times in 5 J.11 increments, starting with a 
concentration of 220 Jlg/ml down to 24 J.1g/ml in a total volume of 10 Jll. Following this, 
10 JlI of the cell-infected virus suspension was incubated with 10 Jil of the diluted extract 
for 1 min prior to infection. 
As a control, the virus-infected cells were lysed by two freeze-thawing cycles, and treated 
with the extract at all dilutions. The ECso value of the control would then be compared to 
that ofthe treated. 
The virus titer was determined by infecting wells, in triplicate, with 10 J.11 of the cell­
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2.3.8 - Neutralization ofthe antiviral activity ofSECOMET V with BSA 
Aim: To investigate the postulate that the antiviral agents could bind non-specifically to 
proteins thereby losing their virucidal properties. The non-specific binding would further 
explain the lack ofspecificity ofSECOMET V. 
An 8% BSA (bovine serum albumin) solution was prepared in tissue-culture grade PBS 
by dissolving 8 gm of BSA in PBS up to 100 rol with the aid of a magnetic stirrer. Equal 
volumes of the BSA solution was then mixed with the extract (1 ml for a total of 2 rol) 
and incubated at room temperature for 1 h. Following the incubation, the extract was 
tested for activity against 10 III of VV at a titer of 108 pfu/rol, in 6-well plates, by 
incubating 10 III of the BSA/extract solution with an equal volume of virus for 1 min 
prior to infection. As a control, BSA alone, extract alone and PBS alone were incubated 
with VV prior to infection. 
2.4 - Characterization of the chemical properties of the active 
agents in SECOMET V 
2.4.1 - Heat inactivation ofSECOMET V 
Aim: The vast majority of proteins are heat-labile. By submitting the extract to 
conditions that would inactivate proteins it would give more weight to the argument that 
the active agents might not be proteins. 
A volume of 1 ml of crude extract was transferred to a microcentrifuge tube and placed in 
~ autoclave for 30 min at 15 psi, 121°C. Once the autoclaving cycle was over, the 
extract was allowed to cool to rlt. A volume of 10 III of the coole<L autoc1aved extract 
was then tested for activity against 10 III of VV at a titer of 108 pfulml in 6-well plates as 
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2.4.2 - Activity-guided size-exclusion fractionation 
Aim: This step allowed us to gain some insight into the physical nature of the antiviral 
agentls present in the extract with respect to their size. If there was activity in the fraction 
below 3 Kda in size, this would give more weight to the argument that the antiviral was 
unlikely to be a protein. 
A volume of 15 ml of crude extract was loaded on the outer chamber of a Centriprep ® 
YM-I0 (10 Kda cut off, Millipore, USA). The device was subsequently placed in a 
centrifuge, and the filtration was driven by centrifugation at 3,500 g for 2 h. 
The material that collected in the inner chamber was tested for antiviral activity by 
incubating with stock virus (106 pfu) with 10 J.lI (at a concentration of 10 mglml) of the 
flow through for I min prior to infecting a confluent monolayer of BSC-l cells in 6-well 
plates. A second identical fractionation step was carried out using the filtrate from the 
first fractionation, but this time usmg a Centricon YM-3 (3 Kda cut-oft) and tested for 
activity in the same fashion. 
2.4.1 - HPLC fractionation 
Aim: To identify the number of antiviral agents in the extract. Furthermore, the 
fractionation behavior of the active agents would provide more insight into their chemical 
nature regarding hydrophobicity. 
The principle of this separation method lies in. the relative hydrophobicity of the desired 
compound with respect to that of the matrix (phenyl-hexyl) and solvent gradient. The 
more hydrophobic the sample, the later it will elute, since only when the hydrophobicity 
of the solvent becomes greater than that of the column resin, will the compounds interact 
more favorably with the solvent than with the column.. Acetonitrile is often the organic 
solvent of choice due to its low viscosity, miscibility with polar solvents and significant 
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For this purpose, a volume of 20 J.lI of the active < 3Kda fraction was loaded into an 
analytical Luna HPLC column, containing phenyl-hexyl as the solid-phase phase matrix, 
5 J.l pore size and 200 x 40 mm (Vydac, Maryland, USA). 
The organic solvent acetonitrile (hydrophobic) was used in conjunction with trifluroacetic 
acid (TFA) to create a gradient of increasing hydrophobicity, using a Kantron® 325 
HPLC apparatus (Kantron Instruments, USA) with the UV detector set at 230 nm. The 
fractionation was carried out over a 60 min period, during which time 0,8 m1 fractions 
were collected at 1 min intervals (in sterile plastic tubes) for the duration of the run for a 
total of 62 fractions. The fractions were then transferred to sterile 1,5 mlmicrocentrifuge 
tubes and dried under a vacuum for 6 h at 55°C. The dried samples were then 
resuspended in 15 J.lI ofPBS and tested against 105 pfulml in 96-well tissue culture plates 
containing confluent mono layers ofBSC-l cells. 
A volume of 10 J.ll of each fraction was incubated with 10 J.lI ofVV (105 pfulml) for 60 s 
prior to infection. Positive fractions with antiviral activity were those that showed 
complete pfu inhibition. 
2.4.4 - TLCfractionation 
Aim: To corroborate the results obtained in HPLC fractionation regarding both the 
number ofactive fractio s and hydrophobicity of such fractions. 
TLC separation exploits similar properties as those in HPLC, except that there is no 
solvent gradient. The positively charged silica matrix will interact via hydrogen bonding 
(more specifically dipole-dipole interactions) with any permissive substances present in 
the extract. More hydrophobic samples will migrate further up the sheet, since they 
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The resolution of the compounds up the TLC sheet is defined as the retention factor (Rf). 
The Rf is measured as the distance traveled by the compound divided by the distance of 
the solvent front and is reproducible as long as the same conditions are used. 
This experiment was carried out using silica sheets (Merck, Darmstadt, Germany) 20 cm 
long and 6 em in width. A total of 10 III of SECOMET V was loaded along a horizontal 
line, 1 cm from the bottom, traced with the aid of a pencil. The loading of the material 
onto the sheet was carried out with the aid of glass capillaries, spotting small amounts at 
a time followed immediately by drying with a hairdryer. The line along which the 
material was spotted was considered the point zero of the solvent front or retention factor 
zero (Rr= 0) and 18 cm above this line, a second line was drawn which indicated the end 
of the fractionation front (Rr= 1, Figure 2.1). 
Once all 10 III were loaded, the sheet was transferred to a glass tank containing 70 % 
acetone, 30 % H20 at a depth of less than 1 cm. Once the solvent front reach the Rf point 
of 1, the sheet was removed from the tank, and was allowed to dry at r/t. Once the sheet 
was dry, it was divided into 18 pieces, each piece 1 cm in length. 
The material was recovered from the sheet with the aid of a wooden spatula, which was 
used to scrap of the silica of each individual sheet. The scraped material was then 
transferred to microcentrifuge tubes, followed by the addition of 300 III of water. To aid 
in the removal of the material from the silica matrix, once water was added, the material 
was vigorously mixed with the aid of a vortex for 2 min. The silica-free supernatant was 
then recovered via centrifugation in a bench-top centrifuge set at 14,000 rpm, for 5 min. 
Once the supernatant was transferred to sterile microcentrifuge tubes, the water was 
removed in a vacuum-drier set at 55 °C for as long as it took to completely dry the 
suspended material (usually 24 h). The dried material was then resuspended in 100 f..ll of 
PBS and assayed for antiviral activity by incubating 10 III of each fraction with 10 f..ll of 
virus (105 pfu/ml) for 60 s prior to infecting BSC-l cells in 96 well tissue culture plates. 
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Figure 2.1: Diagrammatic representation of a resolved TLC sheet. The material was spotted at 
the origin, and once the solvent migrated the pre-determined distance (18 cm, Rc = 1), the sheet 
was probed for the desired compound. In this example, the compound migrated 4 cm from the 












Chapter 3: Results 
Chapter Three 
3.0 - RE8ULT8 
3.1 - Determination ofthe dry weight ofSECOMET V 
Briefly, 6 microcentrifuge tubes were weighed (Table 3.1). A volume of 200 III of the 
crude extract was dispensed into half of the microcentrifuge tubes. In parallel, an equal 
volume of the 3 Kda size-fractionated extracted was added to the remaining 3. After 
recording the weight of the tubes + extract, the samples were placed in a drier for 8 h. 
Once the time elapsed, the tubes were re-weighted and placed again in the drier for a 
further 8 h. If there was no change in weight from the first to the second drying cycle, the 
samples were considered dry. 
The actual dry weight of the samples was obtained by subtracting the weight of the 
samples prior to drying, with that of the dried samples. This then allowed for the 
calculation the concentration of the samples, expressed in mg/ml. The concentration of 
the crude material was 22,0 mg/ml whereas that of the < 3 kda fraction was 10 mg/ml 
(Table 3.1). 
Table 3.1: Detennination of the dry weight of the crude and <3 Kda extract material. The 
individual weight of each tube was recorded prior to adding the liquid samples. Two identical 
drying cycles were carried out to nsure complete removal ofthe carrying medium. 
Weight (mg) 
Fraction Tube Tube + dry Tube + dry Dry Average ! Conc. 
sample 1 st cycle • sample 2nd cycle (mg/ml) 
Crude 940,0 945,0 945,0 5,0 
939,0 943,0 943,0 4,0 4,33 22,0 
942,0 947,0 947,0 5,0 • (±2,8) 
<3Kda 1138,0 1140,0 1140,0 2,0 
1144,0 1146,0 1146,0 2,0 2,0 10,0 
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3.2 - Investigation ofthe anti-Wproperties ofthe extract. Inhibition ofadsorption or 
replication: A diagnostic-type assay 
When the extract was received, it was necessary to determine if it inhibited cell-free 
virions or it interfered with viral replication. For the fonner, 10 Jll (220 Jlg) of the crude 
extract was incubated with 10 JlI ofVV (l08 pfulml) for 60 s prior to infection (assay A). 
In a parallel experiment, the monolayer was first infected with 10 JlI of VV at a titer of 
104 pfulm1. An equal volume of extract (20 Jll, 440 Jlg) was then added, 90 min later, 
once virus had adsorbed (assay B). The absence of pfu in A and presence in B indicated 
that the extract was exerting its antiviral effect prior to the adsorption event, neutralizing 
cell-free virions. Based on these findings, all further assays would be carried out by 
incubating the virus with the extract prior to infection rather than adding extract post 
infection. 
3.3 - Cytotoxieity assay: Determination ofCCso and working dose 
To shed further light into the properties of the extract, it was necessary to establish a 

working dose by doing a cytotoxicity study. 

For this study, 96-well rather than 6-well plates were used. Starting with an initial 

concentration of 2200 Jlglml, the extract was diluted in 220 Jlglml increments for a total 

of 11 dilutions. The cells were exposed to the extract for a period of 24. Following thi~, 

the number of viable and non-viable cells were scored using the trypan blue dye 

exclusion method. The concentration of the extract that reduced cell viability by 50 % 

was determined from the graph as 560 Jlglml ±70 (Figure 3.1). Based on these findings, 
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Figure 3.1: Effect of varying concentrations of the extract in cell viability. Confluent monolayers 
of BSC-l cells (±105 cells/well) in 96-well plates were treated with varying concentrations of 
extract or PBS as a controL After 24 h of incubation the overlay medium was discarded and the 
monolayer was washed twice with 100 )!J of PBS, rinsed once with 20 III of trypsin, and the cells 
were brought into suspension with an equal volume of trypsin following a 20 min incubation at 
37°C, 5% CO2• Cells were then incubated with an equal volume of trypan blue for 5 min and 
scored under an inverted microscope at a x20 magnification. The CCso was calculated from the 
curve as 560 Ilglml ±70. (Results were an average 00 independent experiments). 
3.4 - ECso assay. 
Once it was detennined that the virus had to be incubated with the extract prior to 
infection, a more qualitative assay was carried out. For this purpose, 10 III of a fixed 
number of pfu (l08 ml) were incubated with decreasing concentrations of extract for 60 s 
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stained and number of pfu was counted (Figure 3.2). The ECso value is the universal 
method to assess the strength ofan antiviral agent. 
Dose-dependent inhibition of CPE: ECso100 
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Figure 3.2: Dose-dependent inhibition of CPE. Vaccinia virus (l08 pfu/ml) at a volume of 10 J.11 
was incubated with decreasing concentrations of the extract, in triplicate, for 60s prior to 
infection. Following a 48 h incubation period, the cells were stained with crystal violet and the 
number of pfu was counted. The ECso of the extract was extrapolated from the graph as 1180 
Jig/ml ± 150. Contro1s included untreated virus and virus treated with PBS. 
3.5 - Inactivation kinetics 
The kinetics of inactivation of the extract was assessed by measuring the time-dependent 
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fixed at 1180 !lglml (the ECso) and the incubation time was manipUlated. Five hundred !ll 
of extract was incubated with an equal volume of VV (108 pfu/ml) for a final 
concentration of 1180 !l-glml. A sample of 20 !ll was taken every min for 10 min and used 
to infect confluent monolayers of BSC·1 cells. There was a 50 % reduction in the number 
ofpfu after 60 s of incubation. After 6 min of incubation, no evidence of cytopathic effect 
was observed. 
100 - - - ---- - - - - - - - - -,.-=-=-.....-........-....--..- - - -­
= ..,=> 80.... Inactivation Kinetics .,..., ~ 
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Figure 3.3: Time·dependent inhibition of CPE. A volume of 500 ~l of virus (108 pfu/ml) was 
incubated with an equal volume of extract at a final concentration of 1180 ~glml. At different 
time points (1-10 min, at 1 min intervals) the monolayer was infected with extract-treated virus, 
in triplicate. As a control, virus was incubated with an equal volume of PBS prior to infection. 
Following a 48 h incubation period, the cells were stained with crystal violet for 1 h and the 
number of surviving pfu was counted. The rate of inactivation was calculated by dividing the 
number of pfu in test wells by that of PBS treated VV in control wells. Half of the virus was 
inactivated in the ftrst minute and no evidence of cytopathic effect indicative of virus replication 
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3.6 - Inhibition ofcell-associated virus 
In this study, BSC-1 cells were infected with VV at a MOl of 0,01. Following 24 h of 
incubation, the cells were harvested. These cells now contained mature, infectious virus 
particles. To minimise the number of cell-free virus particles, the cells were washed 3 
times with PBS. The harvested cells were then used in infectivity assays. By exposing the 
cells to increasing concentrations of antiviral for 10 min prior to infection, the 
effectiveness of the extract was assessed in neutralizing cell-associated virus and 
interfering with viral infection from infected to uninfected cells. It was clear from the 
results that the extract had no impact on either cell-bound virus or transmission from 
infected to uninfected cell (Figure 3.4). 
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Figure 3.4: Inhibition of cell-associated virus. Cell-aSsociated virus was prepared by infecting a 
cell monolayer in a 25 cm2 flask with 3xl04 pfu (MOl of 0.01) for 24 h. The cells were then 
harvested by scrapping and resuspended in 1 ml of fresh, pre-warmed MEM. From this stock of 
cell-associated virus, a volume of 10 III was used and incubated with an equal volume of 
difference concentrations of extract for 10 min prior to infecting BSC-l cells in 96-well plates. As 
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with 220 ,....g/ml. Also, as part of the control, the cells containing virus were treated with an equal 
volume of PBS prior to infection. The virus titer was detennined by infecting cell monolayers 
with untreated cell-associated virus. 
Following 48 of incubation, the weBs were individually stained with 30 III of crystal violet and 
the number of pfu was counted. The graph illustrates the number ofpfu that survived treatment (y 
axis) with a given concentration ofextract (x axis). 
3.7- Neutralization ofthe antiviral properties ofSECOMET V with BSA 
For tIlls purpose, an 8 % BSA solution was prepared in PBS and added equal volumes of 
the solution and the extract. Following a 1 h incubation period at rlt 10 ,....1 of the solution 
was mixed with 10 ,....1 of VV (l08 pfu/ml) for 10 min prior to infection. As controls, VV 
was incubated with either PBS alone or 8 % BSA in PBS. It was observed that neither the 
presence of BSA nor PBS negatively impacted on virus infectivity indicated by the 
presence of 108 pfu/ml on both assays. As a positive control, the virus was incubated with 
the extract for 10 min prior to infection. The absence of plaques indicated a virucidal 
effect exerted by the extract. However, when extract was treated with BSA, it lost its 
ability to neutralize VV, as indicated by the presence of an equal virus titer (l08 pfu/ml) 
in both test and control wells. 
3.8 - Heat inactivation ofSECOMET V 
When SECOMET V was tested for activity after being exposed to a temperature of 121 0 
C and a pressure of 15 at for 30 min, it was observed that it had not lost a measurable 
amount of activity. It completely inhibited plaque formation when tested against 108 
pfu/ml in 6-well plates. These results were a clear cut indication that exposure of the 
extract to conditions that would otherwise inactivate the activity of proteins, did not 
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3.9 - Activity-guided size-exclusion fractionation 
This assay was carried out to gain some insight into the nature of the antivirals. A volume 
of 10 IJ.I of the size-fractionated extract was incubated with an equal volume of stock 
virus (108 pfu/ml) for 60 s. After the incubation, BSC-l cells in 6-well plates were 
infected with the virus/extract stock. As controls, virus was incubated with dH20 instead 
of extract or an equal volume of crude, unfractionated extract, prior to infection. The 
absence ofplaques in the < 10Kda and < 3 Kda fractions indicated that the antivirals were 
smaller than 3 Kda in size. 
3.10 - HPLCfractionation 
Analytical fractionation of SECOMET V using a hydrophobic phenyl-hexyl solid-phase 
resin and acetonitrile-TF A in a gradient of increasing hydrophobicity as the liquid-phase 
solvent, yielded two active fractions that eluted after 42 and 56 min respectively. The 
time-gap of elution between the two active samples indicated that they were different 
compounds; the one eluted first being more hydrophilic than the second. Furthermore, the 
active compounds did not absorb light at a wavelength of 230 nm, as observed by the 
absence of distinct peaks at the time of elution of the antiviral agents (Figure 3.5). All 
other samples showed no measurable activity against VV, as observed by the presence of 
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Figure 3.StHPLC fractionation of SECOMET V. Using an analytical phenyl-hexyl column as 
the solid-phase matrix and an acetonitrile-TF A gradient of increasing hydrophobicity, SECOMET 
V was fractionated in a time-dependent fashion over 60 min. Fractions were collected' in 1 min 
intervals (0,8 mJ/fraction) for a total of62 fractions. The fractions were dried under vacuum at 55 
°C for 24h. The precipitated material was then resuspended in PBS and tested for activity as 
described (Chapter 2, section 2.3.3) against 105 pfu/m!. Two active fractions were obtained at 42 
and 54 min respectively. 
3.11 - TLCfractionation 
The resolution pattern of SECOMET V on silica sheets using 70 % acetone as the 
solvent, yielded 2 active fractions out of a total of 18 tested. The fIrst active fraction was 
recovered less than 1 cm from the start of the solvent front (Rr value between 0,0-0,05), 
whereas the second antiviral resolved a further 5 cm up the silica sheet (Rr between 0,33­
0,38). This clearly indicated the presence of at least 2 antiviral agents, which could be 
:fractionated based on hydrophobicity. The fraction that migrated the furthest eRr between 
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.. ChaQter: Eour: 
4.0 - DISCUSSION 
4.1 - Determination ofthe dry weight ofthe extract 
The plant extract (SECOMET V) was produced in a bioreactor from primary plant stem 
cells. It was supplied in liquid form, and the dry weight was not known. It was necessary 
to determine the dry weight in order to generate quantitative data that could be 
independently verified. 
The reason why two identical drying cycles were used was to ensure that there was 
complete removal of any trace solvent. If there had been any further drop in weight 
following the second drying cycle compared to the first, the sample would be dried as 
often as needed until there was no detectable variation in weight. This clearly did not 
happen as illustrated in table 3.1. 
Once it was established that the dry weight was 22 mg/mI, the remainder or the batch 
(approximately 30 ml) was carefully labelled and stored to avoid confusion with other 
batches received later. All work was then carried out using this batch exclusively, since 
the degree ofactivity varied from batch to batch (data not shown). 
4.2 -Investigation ofthe anti-Wproperties ofthe extract. Inhibition ofadsorption or 
replication: A diagnostic-type assay 
In order to further characterize the plant extract, it was crucial to have some insight into 
its mode of action. There were two possible hypotheses: it could either interfere with viral 
replication or it could neutralize cell-free virions prior to infection. The extract could also 
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necessary for virus entry or it could induce an antiviral state within the cell, thereby 
interfering with virus replication. 
Firstly, the attention was focused on direct interference with the virus. The results showed 
that the extract disrupted cell-free virus rather than interfering with the replication 
machinery. Had the extract had an impact on the replication cycle ofVV, a drop in the 
number ofpfu would have been observed. 
4.3 - Cytotoxicity assay: Determination ofCCso and working dose 
This was a quantitative study on the impact of the extract on cell viability. It is known 
that any antiviral agent, regardless of how it exerts its effect, at a given concentration has 
a negative effect on the host cells. By determining the concentration at which a given 
antiviral agent becomes toxic to the BSC-l host cells, an in vitro working dose can be 
established. 
The cytotoxicity index or CCso refers to the concentration of the test substance required 
to kill 50 % of a given cell population. Once this value was determined at 560 Ilglml ±70, 
all further work was carried out at concentrations below this value. This was because if 
more extract was used than what the cells could tolerate, no useful data could be 
extracted simply because the cells would not be viable. Furthermore, it is important to 
point out that the CCso value is inversely proportional to the degree of toxicity incurred 
by the antiviral agent tested. That is, the higher the CCso the lower the toxicity effect of a 
given substance, because the cells can tolerate higher concentrations of the agent before 
being adversely affected. 
The calculated CCso value for the extract was not a direct reflection of the true CCso 
value of the active antiviral agents. In view of the fact that the extract was a 
heterogeneous mixture ,of several dozen, probably hundreds of different compounds, the 
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hand it could also be higher, since there may be substances other than the antivirals that 
are quite noxious to mammalian cells, even more so than the antiviral agents. 
It is widely known that tannins are very ubiquitous in the plant kingdom and also have 
broad-range activity against viruses, prokaryotic and eukaryotic pathogens; however, they 
are also somewhat toxic to mammalian cells (reviewed in Cowan MM, 1999). Based on 
this knowledge, it was reasonable to speculate that some 'of the toxicity exhibited by the 
extract may be due to the effect of tannins and other cytotoxic substances. On the other 
hand one cannot neglect the likelihood that other cytotoxic agents could have been less 
toxic than the antiviral/so In this case, the CC50ofthe purified antiviralls would have been 
lower. 
The cytotoxicity value of the SECOMET V extract was within the range reported for 
other extracts showing antiviral activity against other viruses. One of the least toxic plant 
extracts which exhibited antiviral activity against human herpes simplex virus 2 (HSV -2) 
was Clinacanthus nutan, which presented a CC50 value of 6,67 mg/ml (Y oosook et al., 
1999). On the other hand, one of the most toxic plant extracts appeared to be that reported 
for Rhus javanica which had a CC50 of 130 Ilg/ml and was active against herpes simplex 
virus type 1 (Kurokawa et a!., 1995). 
4.4 - ECso assay 
The significance of the information provided by this study was to determine the strength 
of the extract as well as to carry out de facto comparisons with other plant extracts. 
As previously stated, the EC50 was a measurement of the concentration of extract that 
inhibited plaque formation by 50%. Furthermore, like the CCso, the ECso was inversely 
proportional to the tate of inhibition. 
As previously stressed, the discrepancy between the ECso (1180 Ilg/ml) and the CCso 
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incubating the antiviral with the extract in a total volume of 20 ,.d prior to infection, the 
actual concentration to which the virus was exposed was 5 times greater than what the 
cells were exposed to. This was because, once the extract/virus suspension was added to 
the cells, the final volume was 100 ,.d, effectively diluting the extract below the CCso 
value. 
The strength of the antiviral was quite high. A comparison between the extract (ECso = 
1180 Jlg/ml) and a knQwn anti-VV agent such as cidofovir ECso = 5 Jlg/mI) may indicate 
otherwise. However, two points must be considered when comparing these two antivirals: 
firstly, cidofovir was tested in its pure form as a homogenous solution, whereas the plant 
extract was a heterogeneous mixture of several dozen, probably hundreds of other 
unknown substances, greatly adding to the overall dry-weight of the solution; secondly, 
most antiviral agents are tested against a comparatively lower virus titer. Such titer 
usually ranges between 102 and 104 pfu, as opposed to 106 used in this study. This was a 
very important difference, as a higher virus titer leads to a higher ECso value, since more 
antiviral would be required to neutralize more pm Had a lower titer been used, the ECso 
would have been equally lower, as clearly described by Baker et al. (2003). 
When comparing these results to those reported by Rao et al. (1969), the potency of 
SECOMET V becomes even more apparent. In their study, they used 106 pfu and 
incubated it with 100 JlI ofa 10 % solution of the Margosa tree leaves for 1 h prior to 
infection. They succeeded in reducing virus titer by 2 logs. On the other hand, a 2,2 % 
solution of SECOMET V reduced virus titer by more than 6 logs, indicating that it was at 
least 104 orders of magnitude stronger than that of the Margosa tree leaf extract reported 
by Rao' s group. 
Semple et al. (1998) carried out a comprehensive screening of Australian medicinal plant 
for activity against a range of unrelated viruses. They used approximately 20 pfu, and 
reported ECsos ranging from 6 Jlg/ml to 250 Jlg/ml depending on the virus and plant. This 
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However, the process of comparing the strength of anti-VV agents across independent 
studies was not very accurate, since there was no standard way set to determine the ECso. 
In light of the arguments presented, it can be safely stated that the plant extract 
SACOMET V was a very potent inhibitor of VV and further work should be pursued to 
identify the active agents so that more studies that are more comprehensive can be 
undertaken. 
4.5 - Inactivation kinetics 
When the rate of VV inactivation was measured in a time-dependent fashion, it was 
observed that the 60 s incubation period that was used to establish the ECso value did not 
reflect the true extent of VV inactivation upon exposure to the extract. In reality, had VV 
been allowed to incubate for longer than 60 s, the ECso value would have been 
significantly lower, since 1180 !lg/ml completely inactivated 106 pfu after 6 min of 
exposure prior to infection (Figure 3.4). Furthermore, had a longer incubation period 
been coupled with a lower virus titer (in the order of 103 pfu) the ECso value would have 
been significantly lower. 
The results obtained from the inactivation kinetics study provide more weight to support 
the statement that the extract SACOMET V was indeed a very strong inhibitor of VV 
infection. 
4.6 -.Inhibition ofcell-associated virus 
As the results of this study clearly illustrate, the plant extract had absolutely no effect 
• 
whatsoever in intracellular mature virions (Figure 3.5). In order for the extract to have 
had any effect on intracellular virus, the antivirals had to be taken up by the cell. This 
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converted it into inactive metabolites. But because the structure of such antivirals were 
not known, it was not possible to draw any conclusions regarding what happened to the 
antiviral/s if they were taken up. 
lbis was the downside of the study, since one of the mechanisms ofVV infection was via 
infection of neighboring cells, without leaving the intracellular milieu (Figure 1.3, step 
10). 
These results give even more weight to the theory that the extract exerts its virucidal 
effect by interfering with cell-free virions prior to adsorption. 
4.7- Neutralization ofthe antiviral properties ofSECOMET V with BSA 
The extract was found to inhibit tobacco mosaic virus (TMV), a plant pathogen that 
infects a wide range of plants (personal communication, Stephen Leivers). The host in 
this case, belongs to the plant kingdom as opposed to that of VV, whose host belongs to 
the animal kingdom. lbis clearly indicated that the antiviral was not specific to VV, but 
rather it had a broad spectrum of activity. 
With these in mind, the rationale in designing the experiment was that the only common 
denominator between these two completely unrelated viruses was the fact that they were 
made up of proteins. Therefore it was plausible to postulate that the antivirals could bind 
non-specifically to proteins. 
The observation that the presence of BSA completely inactivated the antiviral activity of 
the extract corroborated the initial theory. 
It was observed that when BSA was added to the extract, a yellow precipitate formed 
almost immediately. lbis was probably attributed to the precipitation ofBSA on contact 
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Based on this, it 'Yas postulated that the precipitation may be due to the fact that the 
antivirals have both hydrophilic and hydrophobic groups, with the polar groups allowing 
for their solubility in an aqueous environment. 
However, it the presence of proteins, which have a very hydrophobic core, the antivirals 
induced their denaturation by coupling with their hydrophobic cores, removing both 
substances from solution, explaining the formation ofan insoluble, inert precipitate. 
4.8 Heat inactivation ofSECOMET V 
It was clear that the antiviral agents were resistant to both high temperatures under 
pressure, conditions that would otherwise denature any proteins. However, non-protein 
antiviral agents are quite stable under such conditions (reviewed in Jassim and Naji, 
2003). It is equally important to stress the fact that SECOMET V was never refrigerated 
or protected. Even under these harsh conditions, no loss in activity with time could be 
detected, since the ECso assays were performed over the course ofone year. 
4.9 - Activity-guided size-exclusion fractionation 
Again, these assays were qualitative assays, in that the goal was to determine whether or 
not the active antiviral compound in the extract was smaller than 3 Kda. Any substance 
below this value was unlikely to be a protein, since it would have to be less than 27 
amino acids in length, a size below that of the minimum folding threshold (Stryer L, 
1996). Furthermore, of all antiviral and anti-microbial agents reported to date, only two 
were proteins, well in excess of 50 amino acids in length (reviewed in Cowan MM, 
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4.10 - HPLCfractionation 
The presence of two active fractions eluted 12 min apart, provided information regarding 
the number and relative hydrophobicity of the active agents. There clearly were at least 
two distinct anti-VV agents, the most polar being eluted fIrst and the least polar 12 min 
later. The phenyl-hexyl column matrix and the 1FA-acetonitrile gradient used proved to 
be very effective in separating the antiviral agents in the extract. Nonetheless, it was 
somewhat surprising to obtain such good separation with a hydrophobic resin, seeing that 
the extract is suspended in water. Furthermore, the late elution of both agents suggests an 
even higher degree of hydrophobicity. 
Clearly, the antivirals must have a hydrophilic and a hydrophobic group, since they were 
soluble in water, but interacted strongly with the column matrix. 
The relative strength of each antiviral could not be established because the amounts 
recovered from the analytical column were too small for more comprehensive studies. A 
preparative column that would bind more material would have been required in order to 
measure the ECso of each active fraction. However, it could be simply argued that this 
barrier could have been overcome had several identical fractionation cycles been carried 
out and the active fractions pooled. In theory this could have been done, but after careful 
consideration, it was decided that this was not feasible. 
No further information could be extracted from this study, seeing that no peaks were 
present at 230 nm at the time of the elution of the active fractions (Figure 3.5). One other 
I 
drawback was that the detector used only had a single diode, which did not allow for the 
use ofmore than one wavelength. Furthermore, the fractions recovered were so small that 
there was not enough of it to carry out a scan in a separate spectrophotometer. 
However, the HPLC protocols developed for this study could be used as a spring board 
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4.11 - TLC fractionation 
Thin layer chromatography also yielded 2 active fractions, perfectly corroborating the 
results obtained in the HPLC fractionation. However, in this case the stationary phase 
was very polar (silica) as opposed to the hydrophobic column (phenyl-hexyl) used in 
HPLC. 
The solvent of choice was random, but with emphasis on a predominantly hydrophobic 
solvent, since in HPLC the antivirals eluted under hydrophobic conditions (see chapter 3, 
section 3.11) and also because it decreases the resolution time. Furthermore, it is 
important to point out that TLC was attempted with other solvents as well, but the one 
that yielded the best results (70 % acetone) was the one reported in this study. 
The fact that one of the antivirals barely migrated up the sheet (chapter 3, section 3.12), 
indicated the presence of a very hydrophilic group. This could possibly have accounted 
for the strong dipole-dipole interaction. Even the second antiviral that migrated 1/3 of the 
way was likely to have significant polar groups. The further they migrated, the least polar 
they were. 
TLC is often used as a quick method to determine the best resolution conditions prior to 
HPLC fractionation. However, in both cases, very good separation of the antivirals was 
obtained with either method. 
4.12 - Concluding remarks 
The characterization of the anti-orthopoxvirus properties of SECOMET V culminated 
with the knowledge that it was a very strong and possibly non-specific inhibitor of cell­
free virus. Furthermore the antiviral effects can be attributed to the presence of at least 
two autoclaving-resistant agents, which were not proteins in nature and could be readily 
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The seemingly lack of specificity opens up the possibility that SECOMET V could be 
active against other, more clinically relevant pathogens such as: human 
immunodeficiency virus (HIV), human herpesvirus (HSV-1 & 2), hepatitis B and C virus 
(HBV & HCV) and rotavirus (leading cause of diarrhea-associated deaths in African 
children) to name a few. Other pathogens, including bacteria and eukaryotes such as 
fungus and parasites should also be included, particularly Plasmodium spp (causative 
agent of malaria). Furthermore, the fact that many plant extracts are active against 
unrelated viruses gives further weight in the argument that SECOMET V could be active 
against other viruses, and therefore should be tested against such pathogens. 
However what should take priority is the isolation and identification of the active agents, 
to ensure that such agents are novel; to avoid working on something that has already been 
characterized. On the other hand, according to the supplier SECOMET SA, the antiviral 
properties of the extract SECOMET V have never been documented. 
It was established that this could be achieved with different conditions. HPLC would be 
the method of choice to separate and isolate the antivirals, since it gives better resolutions 
and allows for much bigger sample volumes. 
The column of choice would be silica, simply because it is many times cheaper than 
phenyl-hexyl. Acetone is also cheaper than acetonitrile, and lower material and 
production cost would reflect in a cheaper, more affordable end product. 
In the meantime, it would be very informative to carry out some in vivo mouse work. One 
could compare how mice responded to oral treatment with the extract in lethal and non­
lethal mice models, using VV. Accentuated differences between control and test mice 
would certainly fuel more in depth studies. It would also provide much needed 
information regarding dose and toxicity, vital data if the extract is to be used in small­
scale human trials. 
Knowing that SECOMET V has been used in folklore medicine to treat humans for many 
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consumption. However, one of the main goals of the company is to use this extract in 
HIV / AIDS patients, thus providing a source of cheap and possibly effective anti­
retroviral agents. Some work is currently being undertaken in this regard, and the results 
so far were extremely encouraging. 
mv / AIDS is a chronic illness requiring patients to take antiretrovirals for life (reviewed 
in Richman, 2001). This fact will be no different for the plant extract. However, 
continuous, non-stop consumption of the extract could lead to serious side-effects, as 
happens with all antiviral agents in clinical use to date (reviewed in De Clercq, 2004). 
The observation that the antivirals from the extract seem to bind to and denature proteins, 
further strengthens this argument. If such results are a true reflection of what happens in 
vivo, then continuous non-stop usage of the extract could prove deleterious. Furthermore, 
traditionally the extract was only used for the duration of time required to treat a specific 
illness. Therefore, it may be safe for therapy lasting a limited time, but no empirical 
information could be obtained regarding safety for long-term therapy. 
According to the supplier, the production cost was relatively low, and much more could 
be done to significantly lower these costs even further. The cost factor is very important 
in the African continent, often restricting the use of life-saving drugs to an elite few. 
If this product is to benefit those in desperate need, than it must be cheap enough so that 
the impoverish nations our continent can afford them. 
Empirical evidence suggests that SECOMET V can be taken orally. Furthermore, the 
finding that neither high temperatures nor light have a detrimental effect on the activity of 
the extract, further lowers production and delivery costs, since it eliminates the need for 
refrigeration at any step along the manufacturing process. 
However, in light of all the information obta.ined with these series of studies, it is 
imperative that more work should be carried out both in vitro and in animal models 












Appendix A: Media and reagents used 
Appendix A 
If 
Media and reagents used: 
BSC-l tissue culture medium (MEM, 10% FCS and antibiotics) 
• 500ml MEM; 
• 50 ml FCS; 
• 5,5 ml antibiotics (100 X solution). 
Crystal violet staining solution 
• 80 ml PBS; 
• 10 ml crystal violet solution (0,01 % in water); 
• 10 ml methanol 
70% acetone for TLC 
• 70 ml acetone; 
• 30 ml water. 
8% BSA solution 
• 800 mg BSA; 










64 Appendix B: Relative hydrophobicity of organic solvents 
Appendix B II II 
Relative hydrophobicity of organic solvents: 
HPLCffLC reference table of the 
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